Literature DB >> 24373819

Central nervous system lymphoma associated with natalizumab.

Angelika Na1, Nick Hall1, Bhadrakant Kavar1, John King2.   

Abstract

Patients with primary central nervous system lymphoma (PCNSL) after treatment with natalizumab have been considered co-incidental. We report another case of PCNSL in a patient where the explosive onset suggests a causal link.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lymphoma; Multiple sclerosis; Natalizumab

Mesh：

Substances：

Year:  2013        PMID： 24373819     DOI： 10.1016/j.jocn.2013.10.018

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN： 0967-5868            Impact factor:   1.961


  7 in total

Review 1.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

Review 2.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 3.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

4.  Glioblastoma in natalizumab-treated multiple sclerosis patients.

Authors:  Fabian Sierra Morales; Robert B Wright; Jorge E Novo; Leonidas D Arvanitis; Dusan Stefoski; Igor J Koralnik
Journal:  Ann Clin Transl Neurol       Date:  2017-06-06       Impact factor: 4.511

5.  Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant.

Authors:  Karine Moineau-Vallée; Justine Rinfret; My Hanh Luu Hoai; Valérie St-Louis; France Berthelet; Laurent Létourneau-Guillon; Émilie Lemieux-Blanchard; Alexandre Prat; Jean-Philippe Adam
Journal:  Curr Oncol       Date:  2020-12-30       Impact factor: 3.677

Review 6.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

7.  The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis.

Authors:  Yara Dadalti Fragoso; Joseph Bruno Bidin Brooks; Mateus Reghin Neto
Journal:  Iran J Neurol       Date:  2017-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.